REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) is a clinical-stage biopharmaceutical company focused on central nervous system and metabolic disorders, including treatments targeting schizophrenia and related conditions. The company filed its 10-K annual report with the SEC on May 22, 2019, under accession number 0001144204-19-027771, reflecting its status as a public reporting company in the healthcare and biopharmaceutical sector. RVPH reached public markets through a business combination transaction, a structure commonly tracked within the SPAC and reverse-merger research space. The company operates in a therapeutic area that has drawn consistent SPAC sponsor interest given the long development timelines and specialized capital requirements of CNS drug development. For full filing history, deal structure data, and sector comparables on RVPH, sign up for complete access at SpacDesk.